手术绝经与社区老年女性衰弱风险:骨质疏松性骨折研究
本研究基于美国社区65岁以上白人女性队列(N=7,699),随访至18年,比较手术绝经与自然绝经女性的衰弱风险。结果显示手术绝经者血清总睾酮较低,但校正年龄、BMI和工具性日常生活能力受损数后,衰弱、衰弱前期和死亡风险均无显著差异,口服雌激素使用亦未改变关联。
要点
- 手术绝经与自然绝经女性衰弱风险无显著差异(aOR=0.94,95%CI 0.72-1.22)。
- 手术绝经者血清总睾酮显著低于自然绝经者(13.2±7.8 vs 21.7±14.8 ng/dL)。
- 口服雌激素使用未改变手术绝经与衰弱风险的关联。
核心结论
- 在绝经后女性中,手术绝经较自然绝经未增加衰弱风险,即使未使用雌激素治疗亦然。
研究设计与样本
- 前瞻性队列研究,随访长达18年,纳入美国4个临床中心的社区居住65岁以上白人女性(平均71.2±5.2岁),N=7,699。
- 手术绝经依据参与者自我报告绝经前接受双侧卵巢切除术确定。
- 基线血清总睾酮数据仅541名参与者可用。
主要发现
- 基线时12.6%报告手术绝经。
- 随访期间22.0%死亡,10.1%被分类为衰弱,39.7%为衰弱前期,28.3%为健壮。
- 手术绝经女性血清总睾酮显著低于自然绝经女性(13.2±7.8 vs 21.7±14.8 ng/dL,p=0.000)。
- 校正年龄、体质指数和工具性日常生活能力受损数后,手术绝经与衰弱(aOR=0.94,95%CI 0.72-1.22)、衰弱前期(aOR=0.96,95%CI 0.80-1.10)和死亡(aOR=1.17,95%CI 0.97-1.42)风险均无显著关联。
- 无证据表明口服雌激素使用改变了上述关联。
临床怎么用
- 对于有手术绝经史的老年女性,不应仅基于绝经类型额外增加衰弱风险评估或干预。
- 临床评估衰弱时,可沿用与自然绝经女性相同的标准,无需因手术绝经而调整。
局限性
- 仅纳入社区居住白人女性,结果外推需谨慎。
- 手术绝经依赖自我报告,可能存在分类偏倚。
- 血清总睾酮数据仅541名参与者可用,样本量有限。
- 口服雌激素使用未改变关联,但其他激素治疗方式未涉及。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine whether women with surgical menopause have a higher risk of frailty than naturally menopausal women. DESIGN: Prospective cohort study with up to 18 years of follow-up. SETTING: Four U.S clinical centers. PARTICIPANTS: Community-dwelling white women aged 65 and older (mean 71.2±5.2) enrolled in the Study of Osteoporotic Fractures (N=7,699). MEASUREMENTS: Surgical menopause was based on participant self-report of having undergone bilateral oophorectomy before menopause. The outcome was incident frailty, classified as robust, prefrail, frail, or death at 4 follow-up interviews, conducted 6 to 18 years after baseline. Information on baseline serum total testosterone concentrations was available for 541 participants. RESULTS: At baseline, 12.6% reported surgical menopause. Over the follow-up period, 22.0% died, and 10.1% were classified as frail, 39.7% as prefrail, and 28.3% as robust. Surgically menopausal women had significantly lower total serum testosterone levels (13.2 ± 7.8 ng/dL) than naturally menopausal women (21.7 ± 14.8 ng/dL) (p=0.000), although they were not at greater risk of frailty (adjusted odds ratio (aOR)=0.94, 95% confidence interval (CI)=0.72-1.22), prefrailty (aOR=0.96, 95% CI=0.80-1.10), or death (aOR=1.17, 95% CI=0.97-1.42) after adjusting for age, body mass index, and number of instrumental activity of daily living impairments. There was no evidence that oral estrogen use modified these associations. CONCLUSION: In postmenopausal women, surgical menopause was not associated with greater risk for frailty than natural menopause, even in the absence of estrogen therapy. Future prospective studies are needed to investigate hormonal mechanisms involved in development of frailty in older postmenopausal women. J Am Geriatr Soc 66:2172-2177, 2018.
引用
- Huang G, Coviello A, LaValley MP, et al. Surgical Menopause and Frailty Risk in Community-Dwelling Older Women: Study of Osteoporotic Fractures. J Am Geriatr Soc. 2018. PMID: 30251302. doi:10.1111/jgs.15505
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。